Member Info for Scharnhorst

It isn’t a year of runway. The interim accounts are dated 31st December. The runway is only 7 months.

Patience is certainly required. It’s a quality company and class will out as they say in racing circles.

No need. Look at how they revived Sheffield Wednesday from a near death experience.

I’m happy to comment on company output but I’m not willing to work to get the share price up. That’s for the company employees. If I was to actively try to get the share price up I feel like it would compromise my integrity. I would have to ignore, or actively lie about, new information that doesn’t fit the positive trajectory narrative. I would no doubt end up saying stupid things like the company’s own broker isn’t telling the truth. I’ll leave that sort of thing to ramping traders. For information the Shore Capital research can be read by taking a free trial to Research Tree.

“Unless we hear otherwise via an official channel, the 7 January 2021 RNS remains the only legal reality. Relying on broker interpretations over official filings only serves to spread unnecessary confusion.”

You’re clearly out of your depth here and not the experienced investor you pretended to be at the outset. Creo aren’t acting illegally by being economical with the truth. There was no lie in stating that MicroBlate has FDA approval as it does. Just not the approval required for Creo to commercialize it with Intuitive YET. Unfortunately it’s common practice nowadays to put additional information into the public domain via company brokers. I’m a shareholder and believe Creo can succeed on merit and doesn’t need spivs hoodwinking inexperienced investors with untruths.

You’re barking up the wrong tree blaming the brokers. The Cavendish statement is indeed factually incorrect and they could change it to say MicroBlate does have FDA approval, but that wouldn’t be the whole truth as they don’t have FDA approval for the robotic surgery with endoscopy. For that reason I would focus on the Shore Capital report as they are joint brokers appointed by Creo. It would be naive to suggest Creo haven’t seen their broker’s report, or had the opportunity to correct any factual errors. Professor Shah is indeed using MicroBlate and collecting clinical evidence, as is the team in Amsterdam. Why do you think both trials are happening in Europe and none in the USA where Intuitive is based and makes the bulk of its revenues?

Quote from research report dated 25th February 2026.

“In the US, although a 510(k) clearance has been obtained from the FDA, this is currently restricted for use in open, laparoscopic or percutaneous procedures (not endoscopic) because of deaths with a competitor product. Once more safety data have been accrued from the ongoing European trials and the post-marketing programme being conducted with Intuitive, CREO expects to engage with the FDA. At this point we would expect that a Breakthrough Device Designation and/or De Novo application be submitted”

Quote from report dated 30th March 2026

“We note that Intuitive Surgical recently announced its FY25 results, stating Ion procedures grew c51% in the year, and while we expect most of the procedure volume to be in the US where MicroBlate flex is not approved, we believe the procedure growth indicates the potential of the lung tumour opportunity.”

Your so called research is superficial. In the RNS you refer to the company did not make it clear that the FDA approval does not cover the endoscopy use. A further FDA application will be required before Creo’s equipment can be used with the Intuitive robotic bronchoscopy. This is not only made clear in the Shore Capital broker research, it is also clearly stated in the Cavendish research. It’s another example of brokers getting better information than the plebs relying on RNS.

In short MicroBlate has FDA approval but it does not cover endoscopy use which is needed by Creo before it can commercialize in the US.

Another clown.

It’s in black and white in the Shore Capital initiation research report published on 25th February 2026. MicroBlate does not have FDA approval for endoscopic use. It is only approved for use in open, laparoscopic or percutaneous procedures so it doesn’t cover robotic broncoscopy work, hence the evidence is being collected prior to FDA submission.

According to the resident AI user, CREOs products have FDA clearance.

While the robotic surgery partnerships are very interesting, the MicroBlate FDA 510(k) authorisation is restrictive and does not cover endoscopy which, of course, is CREOs use case. As such, they are collecting clinical evidence with a view to making a new FDA application in 2027 with hoped for commercialisation in 2028 (not later this year as the ramper suggests).

“Thank you for your effort” lol.

Dear Claude…

Good post drbiotech. I think it’s a super company and has then products to thrive. It may take a bit longer than equality’s AI manipulative slop is saying but I feel sure they’ll get there.

I have equals down as a spiv. If it’s his fanciful cash projections versus the company’s financial track record I’ll give more weight to the latter thanks all the same.

Thumbs up to Senator1. I suspect the CFO lacks credibility to those who took part in previous placings having swallowed his projections. While he’s there I would do a final raise, major shareholders demand his head, sorry but goodbye, appoint a higher calibre individual which shouldn’t be difficult, problem solved imo.

I’ve just read that Wes Streeting was treated for kidney cancer. He’s on a mission.

The company thinks the shares aren’t worth more than 2.25p, at which they were happy to raise in December. That tells you there is no meaningful increase in paying customers. Last September they admitted that the number of paying users had declined. “697 paying customers have signed up to elevate.io with 344 of these paying at 26 September 2025.” Since then they’ve stopped talking about payers. The CEO is a clown.

As I understand it a NICE mandate isn’t legally enforceable.

While NHS bodies would be expected to follow a mandate that would deliver cost savings, I suspect they don’t have to jump as soon as it is released.

I think the products are mind blowing. I’ve had keyhole surgery on my oesophagus twice and while it’s far better than being opened up with a large incision, the surgeon still has to make 5 puncture wounds to get all the kit in, including a gas tube to bloat you up so the surgeon can see what he’s doing. Furthermore I needed separate visits for an endoscopy. Being able to have an endoscopy, then treatment through the endoscopy tube on the same day, then being able to leave that day would have been brilliant for me and the NHS given the well publicised bed shortages. Being opened up from the outside also introduces more risk of picking up an infection. What Creo enables, especially in treatment of lung and pancreatic cancer, feels like Dr Bones Star Trek stuff.

They are certainly delayed given they told us they would be announcing results mid-January. As investors were therefore expecting results this week, I can understand a bit of frustration when news of the delay to March was sprung on them yesterday. Psychologically, I feel it would have been better to give a heads up say a couple of weeks ago, but I have no idea when the auditors told them they’d need more time.